Physician profile
Luis A Umana
NPI 1710145362
$1,320.44
in general payments reported to CMS, 2019-2025
11 companies · $78.90 in 2025
The $78.90 reported for 2025 was less than what a typical Medical Biochemical Genetics provider received nationally (typical 2025 total: $149).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $155 · 2021: $125 · 2022: $266 · 2023: $98.47 · 2024: $123 · 2025: $78.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $479.48 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $300.00 | 2019 | |
| Horizon Therapeutics Plc | $176.62 | 2022-2023 | Ravicti |
| Takeda Pharmaceuticals U.S.A., INC. | $115.08 | 2020-2024 | Vpriv |
| Genzyme Corporation | $85.20 | 2019-2025 | |
| Travere Therapeutics, INC. | $73.55 | 2019-2024 | Cholbam |
| Ptc Therapeutics, INC. | $27.97 | 2025 | Sephience |
| Orchard Therapeutics North America | $26.48 | 2025 | Lenmeldy |
| Shire North American Group INC | $19.04 | 2019 | |
| Dexcom, INC. | $17.02 | 2024 | Dexcom G6 Transmitter |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Umana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.